BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 9, 2025
Home » Authors » Anette Breindl

Articles by Anette Breindl

Dinosaur illustration

In assessing shared genetic risk, love can look like pleiotropy

Nov. 17, 2022
By Anette Breindl
Social scientists are well aware of the consequences of what’s called assortative mating – that is, the fact that marriages tend to occur between people who are similar in things such as interests, social status, education and wealth. Biologists, on the other hand, have tended to ignore it.
Read More
Tumor microenvironment
Cancer

Cancer cells use, impersonate neurons to grow

Nov. 17, 2022
By Anette Breindl
Two studies published this week have reported new insights into the role of the nervous system in tumors outside of the brain. Researchers at the Shanghai Jiao Tong University School of Medicine have identified a role for pain-sensing neurons in helping oral carcinomas cope with nutrient starvation, and that this interaction could be blocked by the calcitonin gene-related peptide (CGRP)-targeting migraine drug Nurtec ODT (rimegepant; Biohaven Pharmaceutical Holding Co. Ltd.).
Read More
Credit: Darryl Leja, NHGRI
Genetic/Congenital

Study hits shared risk between schizophrenia, bipolar disease on the nose

Nov. 15, 2022
By Anette Breindl
Researchers have identified miR-124 signaling and its effects on AMPA receptor neurotransmission as a biological mechanism linking the shared risk scores of schizophrenia and bipolar disorders to their shared symptoms. The work, which appeared online in Neuron on Nov. 14, 2022, focused on schizophrenia and bipolar disorder, which are both highly heritable disorders that share substantial risk. Beyond their implications for those two specific disorders, the findings illustrate a path to connecting risk scores and behaviors via their biological link.
Read More
Killer T cells (green and red) surround a cancer cell (blues)
SITC 2022

Business is shaky, but science is groundbreaking for engineered T-cell study

Nov. 11, 2022
By Anette Breindl
In August, Pact Pharma Inc. suspended its phase I trial after 16 patients had been treated with its autologous CRISPR-edited T cells “for business reasons,” the company announced at the time. Scientifically, though, the trial broke enough new ground to be concurrently presented in a late-breaking oral session at the 2022 annual meeting of the Society for the Immunotherapy of Cancer (SITC) and published as an accelerated article preview in Nature on Nov. 10, 2022.
Read More
Triglyceride fat accumulated inside liver cells
Endocrine/Metabolic

At AASLD 2022, polygenic risk score subtypes in NAFLD

Nov. 8, 2022
By Anette Breindl
Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of the American Association for the Study of Liver Diseases 2022 meeting (AASLD 2022), new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and nongermline mutations.
Read More
Liver illustration

At AASLD 2022, polygenic risk score subtypes NAFLD

Nov. 7, 2022
By Anette Breindl
Modern molecular techniques have progressed to the point where sequencing can seem almost quaint. At the Basic Science Symposium of The Liver Meeting 2022, new techniques were on full display, with sessions devoted to epigenetics, microbiome analysis and spatial transcriptomics. But the first session was still on genetic variants in all their forms – rare variants, common variants and non-germline mutations.
Read More
Colorized scanning electron micrograph of E. coli bacteria.
Endocrine/Metabolic

AASLD 2022: Robust microbiome engineering enables mechanistic insights

Nov. 7, 2022
By Anette Breindl
High hopes rest on manipulating the gut microbiome in order to treat a multitude of disorders. Clinical validation for the idea has come from the success of fecal microbiome transplants to treat chronic Clostridium difficile infections. Such transplants are in clinical trials to treat other gastrointestinal disorders, and more targeted methods to manipulate the microbiome are being developed as well, not just for infections, but in a multitude of other indications. Targeting the gut microbiome may turn into a way to alleviate inflammatory bowel disease, food allergies, and even psychiatric conditions.
Read More
Brain illustration

‘On-demand’ epilepsy gene therapy selectively calms hyperactive cells

Nov. 4, 2022
By Anette Breindl
By pairing the expression of an inhibitory ion channel with an activity-dependent promoter, researchers have developed the first on-demand gene therapy that specifically silenced hyperactive cells and prevented epileptic seizures.
Read More
Illustration demonstrating how activity-dependent gene therapy works in the brain.
Neurologic/Psychiatric

‘On-demand’ epilepsy gene therapy selectively calms hyperactive cells

Nov. 4, 2022
By Anette Breindl
By pairing the expression of an inhibitory ion channel with an activity-dependent promoter, researchers have developed the first on-demand gene therapy that specifically silenced hyperactive cells and prevented epileptic seizures. The channels are expressed when the promoter is turned on by excessive neuronal activity, and so “we can’t stop the first seizures,” Dimitri Kullmann told BioWorld.
Read More
Brain illustration

‘On-demand’ epilepsy gene therapy selectively calms hyperactive cells

Nov. 3, 2022
By Anette Breindl
By pairing the expression of an inhibitory ion channel with an activity-dependent promoter, researchers have developed the first on-demand gene therapy that specifically silenced hyperactive cells and prevented epileptic seizures.
Read More
Previous 1 2 … 23 24 25 26 27 28 29 30 31 … 391 392 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 8, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • Illustration of cancer tumor on pancreas

    PIKfyve enzyme is target to ‘starve’ pancreatic cancer cells

    BioWorld
    A metabolic vulnerability of pancreatic ductal adenocarcinoma (PDAC) could be used to address this type of cancer that often resists treatments. Scientists at the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing